Jean-Luc M. Lemercier - May 17, 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, EMEA, Canada, Latin Amer
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 17, 2021
Transactions value $
-$68,549
Form type
4
Date filed
5/19/2021, 04:31 PM
Previous filing
May 12, 2021
Next filing
Nov 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +10.6K +7.48% $0.00 153K May 17, 2021 Direct F1
transaction EW Common Stock Tax liability -$12.8K -143 -0.09% $89.49 153K May 17, 2021 Direct
transaction EW Common Stock Tax liability -$55.8K -623 -0.41% $89.49 152K May 17, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -10.6K -100% $0.00* 0 May 17, 2021 Common Stock 10.6K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.